Tag: HEA MTC MEQ BIO

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

− Results show delivery of high radiation doses to tumours compared with normal organs.− Observed normal organ absorbed dosimetry results may allow administration of...

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

− Results show delivery of high radiation doses to tumours compared with normal organs.− Observed normal organ absorbed dosimetry results may allow administration of...

Intrinsic Therapeutics, Inc. Announces That ISASS Has Issued Updated 2025 Recommendations and Coverage Criteria for Barricaid Bone-Anchored Annular Closure

BOSTON, June 19, 2025 /PRNewswire/ -- Intrinsic Therapeutics, a medical technology company committed to redefining the standard of care for lumbar discectomy patients with...

Medical Biomimetics Market Share Set to Cross $55.36 Billion by 2030 with 7.6% CAGR- Exclusive Study by The Research Insights

CHICAGO, June 17, 2025 /PRNewswire/ -- The Global Medical Biomimetics Market is projected to be valued at USD 35.68 billion in 2024 and reach USD 55.36 billion by 2030, growing...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsHEA MTC MEQ BIO

Queen Máxima of the Netherlands Appointed Chair of Global Finance & Technology Network’s International Advisory Board

Volta Labs Expands Presence in the Nordic Region with Callisto Placement at Norway’s Norwegian Sequencing Centre, University of Oslo

Planisware accelerates its development in Asia and announces the opening of an office in Seoul

Tag: HEA MTC MEQ BIO

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

Intrinsic Therapeutics, Inc. Announces That ISASS Has Issued Updated 2025 Recommendations and Coverage Criteria for Barricaid Bone-Anchored Annular Closure

Medical Biomimetics Market Share Set to Cross $55.36 Billion by 2030 with 7.6% CAGR- Exclusive Study by The Research Insights

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us